Related Experiment Video
Updated: May 23, 2026
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer
Carlo Genova1, Erika Rijavec, Giulia Barletta
1National Institute for Cancer Research, Lung Cancer Unit, Genova, Italy.
Introduction:
Non-small cell lung cancer (NSCLC) is one of the main causes of cancer-related deaths worldwide. Although new therapies have become available, innovative treatments are still needed for advanced disease. Ipilimumab , a monoclonal antibody targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), enhances the immune response against the tumor mass and has been proven effective against malignant melanoma.
Areas Covered:
The authors explored the role of ipilimumab in NSCLC using a literature review. The clinical trials involving ipilimumab for lung cancer have shown progression-free survival (PFS) benefits. The use of ipilimumab is related to unusual adverse events resulting from increased or excessive immune activity. Because ipilimumab shows unique response patterns, more suitable criteria known as immune-related response criteria (ir-RC), different from RECIST and WHO criteria, are required.
Expert Opinion:
Although NSCLC is not known as an immunogenic-mediated malignancy, in the past few years, the authors have observed an increasing interest in the development of therapies able to modulate the immune response including vaccines and non-specific immunoregulatory drugs (such as ipilimumab). Ipilimumab may become a new, powerful strategy for the management of NSCLC patients. Further investigation is needed to confirm the optimal treatment schedule and determine the potential predictors of response to the CTLA-4 blockade.
Insights
Ipilimumab, a CTLA-4 inhibitor, shows promise for advanced non-small cell lung cancer (NSCLC) by enhancing immune response. Further research is needed to optimize its use and identify patient predictors for this novel NSCLC treatment.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Research
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally.
- Advanced NSCLC necessitates innovative therapeutic strategies beyond current treatments.
- Ipilimumab, a CTLA-4 targeting monoclonal antibody, has demonstrated efficacy in other malignancies like melanoma.
Purpose of the Study:
- To review the role and potential of ipilimumab in treating non-small cell lung cancer.
- To evaluate the efficacy and safety profile of ipilimumab in NSCLC patients.
- To discuss the need for specialized response evaluation criteria for immunotherapies.
Main Methods:
- A comprehensive literature review was conducted to explore ipilimumab's application in NSCLC.
- Clinical trial data on ipilimumab for lung cancer was analyzed.
- The study examined adverse events and response patterns associated with ipilimumab.
Main Results:
- Clinical trials indicate progression-free survival (PFS) benefits with ipilimumab in NSCLC.
- Adverse events are linked to heightened immune activity.
- Unique response patterns necessitate the use of immune-related response criteria (ir-RC).
Conclusions:
- Despite NSCLC not being traditionally considered immunogenic, there's growing interest in immune-modulating therapies like ipilimumab.
- Ipilimumab presents a potential new therapeutic strategy for NSCLC management.
- Further studies are required to establish optimal dosing and identify predictive biomarkers for CTLA-4 blockade response.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...